Exchange: NASDAQ·Updated 07:30 PM EDT

AXGN News

News
all
press releases
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)
The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
More News
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the WeekPR NewswireVANCOUVER, BC, Oct. 3, 2026VANCOUVER, BC, Oct. 3, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Big...
PR Newswire
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Axogen is acquiring BioCircuit Technologies for $200 million to add sutureless NerveTape to its portfolio, funded by a public stock offering.read more...
Benzinga
Axogen To Acquire BioCircuit Technologies
(RTTNews) - Axogen (AXGN) has entered into a definitive agreement to acquire BioCircuit Technologies, a privately held medical device company and developer of NerveTape, the first FDA-approved device for sutureless nerve repair. Axogen will acquire BioCircuit for total considerat...
Nasdaq News: Markets
Axogen (AXGN) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of +33.33% and +4.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology
Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology PR...
PR Newswire
NZS Capital Added Axogen (AXGN) as an Optionality Position
NZS Capital Added Axogen (AXGN) as an Optionality Position...
Yahoo! Finance: News
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam...
Yahoo! Finance: News
AxoGen (NASDAQ:AXGN) Cut to "Hold" at Wall Street Zen
Wall Street Zen cut AxoGen from a 'buy' rating to a 'hold' rating in a research note on Saturday...
MarketBeat

Advertisement|Remove ads.